ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

filgotinib

Also written as “Filgotinib”, “GLPG0634” and “GLPG0634 50 mg”.

Its studies are mostly in Arthritis, Rheumatoid · Crohn Disease · Colitis, Ulcerative · Arthritis, Psoriatic · Arthritis, Juvenile, led by 3 companies.

Drug pageGLPG0634: every studyAll 50 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 22, 201646 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lakefront Biotherapeutics NV230 open or runningphase 3since Sep 22, 2016Aug 10, 2010none ahead
Gilead Sciencesits history only160 open or runningphase 3since Aug 17, 2016Aug 17, 2016none ahead
Alfasigmaits history only74 open or runningphase 3since Sep 22, 2016Sep 22, 2016Jun 2027phase 3 · NCT07554495

Also a collaborator on its studies: Ono Pharmaceutical.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Lakefront Biotherapeutics NV only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Aug 10, 2010.

  1. Jun 26, 2013Phase 2 study in Arthritis, RheumatoidNCT01888874 · 599 enrolled · United States, Argentina, Australia and more
  2. Jul 4, 2013Phase 2 study in Arthritis, RheumatoidNCT01894516 · 287 enrolled · United States, Argentina, Australia and more
  3. Aug 2, 2013Phase 1 study in HealthyNCT01915667 · 12 enrolled · Belgium
  4. Jan 27, 2014Phase 2 study in Crohn DiseaseNCT02048618 · 175 enrolled · Belgium, Czech Republic, France and more
  5. Feb 14, 2014Phase 2 study in Arthritis, RheumatoidNCT02065700 · 739 enrolled · United States, Argentina, Australia and more
  6. Mar 9, 2014Phase 1 study in Renal InsufficiencyNCT02084199 · 24 enrolled · Germany
  7. Jun 11, 2014Phase 1 study in HealthyNCT02162355 · 36 enrolled · United Kingdom
  8. Sep 22, 20162 phase 3 studies in Crohn DiseaseNCT02914600, NCT02914561
  9. Mar 30, 20172 phase 2 studiesNCT03117270, NCT03101670
  10. Jun 26, 2017Phase 2 study in Inflammatory Bowel DiseasesNCT03201445 · 139 enrolled · United States, Australia, Austria and more
  11. Oct 20, 2017Phase 2 study in Arthritis, PsoriaticNCT03320876 · 122 enrolled · Belgium, Bulgaria, Czechia and more
  12. Apr 19, 2019Phase 2 study in Arthritis, RheumatoidNCT03926195 · 109 enrolled · Bulgaria, Czechia, Estonia and more
  13. Jul 26, 2022Phase 3 study in Colitis, UlcerativeNCT05479058 · 22 enrolled · United States, Belgium, Czechia and more
  14. Sep 11, 2023Phase 1 study in BioavailabilityNCT06043739 · 12 enrolled · Canada

TargetBeta

“An orally bioavailable inhibitor of the tyrosine kinase Janus kinase 1 (JAK1), ”NCIt, by rule
“Tyrosine-protein kinase JAK1 inhibitor; Tyrosine-protein kinase JAK2 inhibitor; Tyrosine-protein kinase TYK2 inhibitor; Tyrosine-protein kinase JAK3 inhibitor”ChEMBL 37, by rule

Other programs on the same 4 targets

ProgramCompanyFurthest phaseStudies
ruxolitinibruleIncytephase 495
tofacitinibrulePfizerphase 494
upadacitinibruleAbbViephase 464
filgotinib maleateruleEisaiphase 42
delgocitinibruleLEO Pharmaphase 321

Studies

All 23 Lakefront Biotherapeutics NV leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06043739Bioavailability · Canada1CompletedOct 27, 202312
NCT05479058Colitis, Ulcerative · United States, Belgium, Czechia and more3TerminatedOct 9, 202322
NCT03926195Arthritis, Rheumatoid · Bulgaria, Czechia, Estonia and more2CompletedAug 14, 2020109
NCT03320876Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more2TerminatedJun 30, 2021122
NCT03201445Inflammatory Bowel Diseases · United States, Australia, Austria and more2TerminatedNov 20, 2020139
NCT03117270Spondylitis, Ankylosing · Belgium, Bulgaria, Czechia and more2CompletedJul 2, 2018116
NCT03101670Arthritis, Psoriatic · Belgium, Bulgaria, Czechia and more2CompletedMar 12, 2018131
NCT02914600Crohn Disease · United States, Argentina, Australia and more3TerminatedAug 1, 20231,188
NCT02914561Crohn Disease · United States, Argentina, Australia and more3CompletedNov 11, 20221,372
NCT02162355Healthy · United Kingdom1CompletedSep 201436
NCT02084199Renal Insufficiency · Germany1CompletedJul 201424
NCT02065700Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedJan 19, 2023739
NCT02048618Crohn Disease · Belgium, Czech Republic, France and more2CompletedNov 2015175
NCT01915667Healthy · Belgium1CompletedSep 201312
NCT01894516Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedMar 5, 2015287
NCT01888874Arthritis, Rheumatoid · United States, Argentina, Australia and more2CompletedFeb 18, 2015599
NCT01820806Healthy · United Kingdom1CompletedApr 20136
NCT01798979Healthy · United States1CompletedApr 201320
NCT01668641Arthritis, Rheumatoid · Hungary, Moldova, Republic of, Russian Federation and more2CompletedSep 201291
NCT01665924Healthy · Belgium1CompletedSep 201236
NCT01419990Healthy · Belgium1CompletedOct 201116
NCT01384422Arthritis, Rheumatoid · Moldova, Republic of2CompletedNov 201136
NCT01179581Healthy · Belgium1CompletedMar 201148

How it is read

Names in the registry

  • “Filgotinib”, 32 entries
  • “GLPG0634”, 11 entries
  • “filgotinib”, 3 entries
  • “GLPG0634 50 mg”, 1 entry
  • “GLPG0634 100 mg”, 1 entry

Codes read as this program: GLPG0634.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.